955
Views
12
CrossRef citations to date
0
Altmetric
Drug Profiles

Cannabidiol as potential treatment in refractory pediatric epilepsy

, , , &

References

  • Papers of special note have been highlighted as:
  • • Of interest
  • •• Of considerable interest
  • Wheless JW. Managing severe epilepsy syndromes of early childhood. J Child Neurol. 2009;24:24S–32S.
  • McTague A, Cross JH. Treatment of epileptic encephalopathies. CNS Drugs. 2013;27:175–184.
  • Szaflarski JP, Bebin EM. Cannabis, cannabidiol, and epilepsy–from receptors to clinical response. Epilepsy Behav. 2014;41:277–282.
  • Cilio MR, Thiele EA, Devinsky O. The case for assessing cannabidiol in epilepsy. Epilepsia. 2014;55(6):787–790.
  • Schlicker E, Kathmann M. Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol Sci. 2001;22:565–572.
  • Falenski KW, Carter DS, Harrison AJ, et al. Temporal characterization of changes in hippocampal cannabinoid CB(1) receptor expression following pilocarpine-induced status epilepticus. Brain Res. 2009;1262:64–72.
  • Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: D9-tetrahydrocannabinol, cannabidiol, and D9-tetrahydrocannabivarin. Br J Pharmacol. 2008;153:199–215.
  • Lutz B. On-demand activation of the endocannabinoid system in the control of neuronal excitability and epileptiform seizures. Biochem Pharmacol. 2004;69:1691–1698.
  • Devinsky O, Cilio MR, Cross JH, et al. Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric conditions. Epilepsia. 2014;55(6):791–802.
  • Ryan D, Drysdale AJ, Lafourcade C, et al. Cannabidiol targets mitochondria to regulate intracellular Ca2+ levels. J Neurosci. 2009;29:2053–2063.
  • Sarafian TA, Kouyoumjian S, Khoshaghideh F, et al. Delta 9-tetrahydrocannabinol disrupts mitochondrial function and cell energetics. Am J Physiol Lung Cell Mol Physiol. 2003;284(2):L298–306.
  • Athanasiou A, Clarke AB, Ae T, et al. Cannabinoid receptor agonists are mitochondrial inhibitors: a unified hypothesis of how cannabinoids modulate mitochondrial function and induce cell death. Biochem Biophys Res Commun. 2007;364(1):131–137.
  • Ryan D, Drysdale AJ, Pertwee RG, et al. Differential effects of cannabis extracts and pure plant cannabinoids on hippocampal neurones and glia. Neurosci Lett. 2006;408(3):236–241.
  • Drysdale AJ, Ryan D, Pertwee RG, et al. Cannabidiol-induced intracellular Ca2+ elevations in hippocampal cells. Neuropharmacology. 2006;50(5):621–631.
  • Ryan D, Drysdale AJ, Pertwee RG, et al. Interactions of cannabidiol with endocannabinoid signalling in hippocampal tissue. Eur J Neurosci. 2007;25(7):2093–2102.
  • Leweke FM, Piomelli D, Pahlisch F, et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry. 2012;2:e94.
  • Izzo AA, Borrelli F, Capsasso R, et al. Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci. 2009;30:515–527.
  • Gomes FV, Llorente R, Del Bel EA, et al. Decreased glial reactivity could be involved in the antipsychotic-like effect of cannabidiol. Schizophr Res. 2015;164:155–163.
  • Izquierdo I, Tannhauser M. Letter: the effect of cannabidiol on maximal electroshock seizures in rats. J Pharm Pharmacol. 1973;25:916–917.
  • Jones NA, Glyn SE, Akiyama S, et al. Cannabidiol exerts anticonvulsant effects in animal models of temporal lobe and partial seizures. Seizure. 2012;21:344–352.
  • Jones NA, Hill AJ, Smith I, et al. Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo. J Pharmacol Exp Ther. 2010;332:569–577.
  • Turkanis SA, Smiley KA, Borys HK, et al. An electrophysiological analysis of the anticonvulsant action of cannabidiol on limbic seizures in conscious rats. Epilepsia. 1979;20:351–363.
  • Consroe P, Benedito MA, Leite JR, et al. Effects of cannabidiol on behavioral seizures caused by convulsant drugs or current in mice. Eur J Pharmacol. 1982;83:293–298.
  • Colasanti BK, Lindamood C 3rd, Craig CR. Effects of marihuana cannabinoids on seizure activity in cobalt-epileptic rats. Pharmacol Biochem Behav. 1982;16:573–578.
  • Gloss D, Vickrey B. Cannabinoids for epilepsy. Cochrane Database Syst Rev. 2012;6:CD009270.
  • Mechoulam R, Carlini E. Toward drugs derived from cannabis. Naturwissenschaften. 1978;65:174–179.
  • Ames FR, Cridland S. Anticonvulsant effect of cannabidiol. S Afr Med J. 1985;69:14.
  • Koppel BS, Brust JC, Fife T, et al. Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2014;82:1556–1563.
  • Cunha JM, Carlini EA, Ae P, et al. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology. 1980;21:175–185.
  • Hussain SA, Zhou R, Jacobson C, et al. Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: a potential role for infantile spasms and Lennox-Gastaut syndrome. Epilepsy Behav. 2015;47:138–141.
  • Porter BE, Jacobson C. Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy. Epilepsy Behav. 2013;29(3):574–577.
  • Mathern GW, Beninsig L, Nehlig A. Fewer specialists support using medical marijuana and CBD in treating epilepsy patients compared with other medical professionals and patients: result of Epilepsia’s survey. Epilepsia. 2015;56(1):1–6.
  • Geffrey AL, Pollack SF, Bruno PL, et al. Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia. 2015;56(8):1246–1251.
  • Saade D, Joshi C. Pure cannabidiol in the treatment of malignant migrating partial seizures in infancy: a case report. Pediatr Neurol. 2015;52(5):544–547.
  • Press CA, Knupp KG, Chapman KE. Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy. Epilepsy Behav. 2015;45:49–52.
  • Englund A, Morrison PD, Nottage J, et al. Cannabidiol inhibits THCelicited paranoid symptoms and hippocampal-dependent memory impairment. J Psychopharmacol. 2013;27:19–27.
  • Welty TE, Luebke A, Gidal BE. Cannabidiol: promise and pitfalls. Epilepsy Curr. 2014;14(5):250–252.
  • Gomes FV, Guimaraes FS, Grace AA. Effects of pubertal cannabinoid administration on attentional set-shifting and dopaminergic hyper-responsivity in a developmental disruption model of schizophrenia. Int J Neuropsychopharmacol. 2014a;18:2.
  • Lisdahl KM, Gilbart ER, Ne W, et al. Dare to delay? The impacts of adolescent alcohol and marijuana use onset on cognition, brain structure, and function. Front Psychiatry. 2013;4:53.
  • Hofmann ME, Frazier CJ. Marijuana, endocannabinoids, and epilepsy: potential and challenges for improved therapeutic intervention. Exp Neurol. 2013;244:43–50. 252.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.